title: Sequence-specific inhibition of gene expression in intact human skin by epicutaneous application of chimeric antisense oligodeoxynucleotides.
abstract: Targeted and selective inhibition of keratinocyte gene expression in human epidermis could be an efficient and safe pharmacologic approach in many skin diseases. In this study we investigated whether topical application of antisense oligodeoxynucleotides (ODN) on intact human skin can be used to inhibit expression of a gene in the differentiated compartment of the epidermis. We applied a variety of 20-mer antisense and control ODN designed to hybridize to different regions on the mRNA of the inducible epidermal proteinase inhibitor skin-derived antileukoproteinase (SKALP)/elafin that was used as a model target gene. When nuclease-resistant fully phosphorothioate ODN were applied to explant cultures of human skin, they were found to be either ineffective at low doses or severely toxic at higher doses which could be attributed to the extremely high degree of protein binding found with this type of ODN. When chimeric ODN with a phosphodiester core and phosphorothioate 5' and 3' ends were applied to intact skin, no toxicity was noted. One of the tested chimeric ODN, that exhibit only minor protein binding, was found to inhibit SKALP expression at the protein level in a dose-dependent manner. The observed inhibition on SKALP expression levels was specific as evaluated by application of strict criteria. Sequence specificity was assessed by the addition of sense and scrambled ODN which were ineffective. Furthermore the expression levels of three other differentiation-related genes (involucrin, cytokeratin 16, and secretory leukocyte proteinase inhibitor) were not affected, indicating that the inhibition was gene specific. Confocal laser scanning analysis of fluorescently labeled ODN confirmed that these molecules can easily penetrate the epidermis and localize in the cytoplasm of differentiated keratinocytes. We conclude that topical application of antisense ODN can be used to modulate epidermal gene expression, and could potentially be useful to inhibit expression of genes that are relevant in skin diseases.
authors.affiliation: Department of Dermatology, University Hospital Nijmegen, The Netherlands. m.wingens@derma.azn.nl
authors.forename: M
authors.initials: M
authors.lastname: Wingens
authors.forename: R
authors.initials: R
authors.lastname: Pfundt
authors.forename: I M
authors.initials: IM
authors.lastname: van Vlijmen-Willems
authors.forename: C A
authors.initials: CA
authors.lastname: van Hooijdonk
authors.forename: P E
authors.initials: PE
authors.lastname: van Erp
authors.forename: J
authors.initials: J
authors.lastname: Schalkwijk
mesh_terms: D000042:Absorption; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives*; D000287:Administration, Topical; D001483:Base Sequence / Q000235:genetics; D002678:Chimera; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D008969:Molecular Sequence Data; D016376:Oligonucleotides, Antisense / Q000235:genetics* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D012867:Skin / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D012879:Skin Physiological Phenomena
chemical_list: D016376:Oligonucleotides, Antisense; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; D000249:Adenosine Monophosphate